Key Highlights

  • Second-quarter Revenue reached $382.5 million, up 22% year-over-year, with GAAP Net Income of $5.6 million marking the company's first profitable quarter.
  • Management raised full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion, with a cash position of $820.7 million at quarter-end.
  • The company received FDA 510(k) clearance for Tempus ECG-PH, its third FDA-cleared cardiovascular AI product, extending its diagnostics platform beyond oncology.
  • Tempus agreed in July 2026 to acquire Personalis for roughly $1.5 billion in enterprise value, aimed at adding molecular residual disease testing capability.

Tempus AI, Inc. (NASDAQ:TEM), the precision-medicine and AI diagnostics company, reported its first GAAP-profitable quarter alongside continued double-digit revenue growth, while advancing a pending Acquisition that would expand its oncology monitoring capabilities.

Tempus AI sits at the intersection of two of the market's most closely watched growth themes: artificial intelligence and precision medicine. The company combines clinical, molecular, and imaging data with AI models to support oncology diagnostics, Drug Development partnerships, and increasingly, cardiovascular and other disease areas.

The company reported second-quarter 2026 results on July 30, 2026, marking a significant profitability milestone alongside continued platform expansion.

Second-Quarter Results

Tempus posted revenue of $382.5 million, up 22% year-over-year, and delivered GAAP net income of $5.6 million, compared with a $42.8 million net loss in the prior-year period, marking its first GAAP-profitable quarter. Adjusted EBITDA came in at $8.0 million, and management raised full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion.

The company reported a cash position of $820.7 million at quarter-end, and for full-year 2025, Tempus generated revenue of roughly $1.27 billion, up more than 83% year-over-year, reflecting the company's sustained growth trajectory.

The Personalis Acquisition

Tempus's July 2026 agreement to acquire Personalis for roughly $1.5 billion in enterprise value, aimed at adding molecular residual disease testing capability, signals an ambition to broaden its oncology monitoring footprint. The deal, announced at $16.25 per share, represents a significant expansion of the company's diagnostic capabilities.

The close and integration timeline of the Personalis acquisition will be a key test of execution as Tempus works to broaden its oncology monitoring capabilities beyond its current platform.

Platform Expansion

Tempus announced it received FDA 510(k) clearance for Tempus ECG-PH, an AI-based tool that analyzes standard electrocardiograms for signs of pulmonary hypertension. The company described it as its third FDA-cleared cardiovascular AI product, extending Tempus's diagnostics platform beyond its core oncology franchise.

Earlier in August, a Nature Medicine publication highlighted strong performance for Tempus's PRISM2 multimodal pathology foundation model, trained on roughly 2.3 million whole-slide images, reinforcing the company's positioning as an AI-first diagnostics platform.

The Investment Case

Bulls point to accelerating revenue, a first GAAP profit, and a large addressable market in AI-driven diagnostics as the company expands beyond oncology into cardiovascular and other disease areas. Wall Street has largely endorsed this view, with several analyst price targets reflecting confidence in the growth trajectory.

The company's improving profitability profile is notable given its history of significant cash burn to build out its genomic sequencing, data, and AI diagnostics infrastructure, marking a meaningful evolution in the business's financial trajectory.

What Comes Next

The close and integration timeline of the Personalis acquisition will be a key test of execution. Tempus's next quarterly Earnings report will show whether the Q2 GAAP profit was a durable inflection point, and progress toward the raised full-year revenue guidance will be closely scrutinized.

Additional regulatory clearances or Partnership announcements in the cardiovascular and oncology AI space, building on the ECG-PH clearance, could serve as incremental catalysts for the platform's continued expansion.

A Profitability Milestone Backs Continued Expansion

Tempus AI's first GAAP-profitable quarter marks a significant milestone for a company that has historically prioritized growth investment over near-term profitability. The company's underlying Business continues to show genuine progress across revenue growth, platform expansion, and diagnostic capabilities.

The pending Personalis acquisition and continued regulatory clearances position Tempus to broaden its platform further, while investors will watch closely for confirmation that the Q2 profitability trend can be sustained.